Merck & Co. Halts Enrollment in Two Keytruda Trials, Citing Deaths

GEN, 13 June 2017
Source: Genetic Engineering & Biotechnology News
“Merck & Co. said it has stopped enrollment in two Phase III trials assessing its cancer immunotherapy Keytruda┬« (pembrolizumab) in combination with other therapies to treat multiple myeloma, following reports of patient deaths. Patients currently enrolled in the two studies will continue to receive treatment, Merck said, adding that its other clinical studies of Keytruda will continue unchanged.”
Find article here.